United States
Healthcare

May 23, 2023

Edward Woo, CFA
(561) 327-9435
ewoo@ascendiant.com

NRx Pharmaceuticals, Inc.

Q1 inline. Key NRX-101 Phase 3 trial progressing well. We believe expected positive milestones and clinical data in 2023 to be strong catalysts for stock. Raising P/T to $5.00.

COMPANY UPDATE

Rating: BUY

Ticker: NRXP

Price: $0.66

Target: $5.00 (from $4.75)

Q1 inline: NRx recently (on May 16) reported its Q1 2023 (ending March) results. Net loss was $11.0 million or EPS of $(0.16) compared with our and consensus estimates of $(0.13) - (0.14). There was no guidance. NRx is a clinical stage drug development company so it generates no revenue.

Operating expenses: Operating expenses were $9.4 million, down slightly from Q4 2022's $10.0 million on continued clinical trial activities.

No guidance: Management did not provide forward guidance.

Adjusting estimate: We are adjusting our 2023 EPS estimate to $(0.56) from $(0.53).

Focused on Bipolar Disorder: Its main drug is NRX-101 (D-cylcoserine/Lurasidone) for the treatment of bipolar depression in patients with suicidality (the risk of suicide). NRX-101 aims to be the first oral therapeutic for the treatment of Bipolar Depression in patients with Acute Suicidal Ideation and Behavior ("ASIB") and Sub-Acute Suicidal Ideation and Behavior ("SSIB").

NRX-101: NRX-101 is a dual-targeted therapy regimen consisting of an initial treatment with NRX-100 (intravenous ketamine) followed by 6-week treatment with NRX-101 (combined DCS and lurasidone). Ketamine is a generic drug and has been widely used for a long time as an antidepressant, although its effect does not last long (usually about a week). NRX-101 is designed to extend ketamine's proven anti-suicidal and antidepressant benefits without its drawbacks.

Large market potential: There is no medicine approved to treat patients with bipolar depression suffering suicidal ideation. According to the NIH, an estimated 2.8% of the U.S. adult population had bipolar disorder in the past 12 months, and the lifetime prevalence is 4.4% of adults in the U.S. Lifetime suicide behavior occurs in 25% to 56% of people with bipolar depression.

Clinical trials data expected in Q4 2023: In Q2 2022, enrollment was initiated in its Phase 2 trial of NRX-101 in patients with Bipolar Depression and Sub-Acute Suicidal Ideation & Behavior (SSIB) (not requiring hospitalization). In January 2023, a registration trial (Phase 3) was initiated for NRX-101 in patients with Bipolar Depression and acute suicidal ideation and behavior (ASIB) (requiring hospitalization). In March 2023, the DSMB (Data and Safety Monitoring Board) examined unblinded study data to assess the study for safety and potential futility and recommended continuation of patient enrollment as planned. This trial has been upgraded to a Phase 2b/3 study that may be used for a registrational filing. Top-line data from this trial is expected in Q4 2023. If the trials are successful, the company may be able to file a new drug application (NDA) with the FDA for NRX-101 by late 2023 or early 2024, with commercialization starting in 2024.

Consolidation of study: Based on guidance from the FDA and the DSMB, the company is consolidating patients in the ASIB study into the currently enrolling Phase 2b/3 trial. This would potentially allow registration of NRX-101 for Suicidal Treatment-Resistant Bipolar Depression, regardless of the mechanism of stabilization. This broader indication may also offer significant advantages in commercialization.

PTSD: NRx plans to investigate NRX-101 in PTSD as an additional indication. The company expects to commence planning for a Phase 2 clinical trial in Q2 2023 with the study initiated in 2023.

Balance sheet: As of Q1, the company has $17 million in cash and $12 million in debt. In Q1, the company raised $3 million in stock (3.8 million shares at $0.75/share). We believe the company has enough cash into 2024.

2023 clinical data can be catalyst: We believe achieving key milestones and strong positive data in 2023 will likely be catalysts for the stock.

Current valuation attractive: We are maintaining our BUY rating, but raising our 12-month price target to $5.00 from $4.75 based on a NPV analysis. This represents significant upside from the current share price and we believe this valuation appropriately balances out the high risks with large upside opportunities.

Company Description

NRx Pharmaceuticals, based in Wilmington, DE, is a clinical stage biopharmaceutical company developing drugs to treat mental health disorders.

Stock Data

Exchange:	NasdaqGM
52-week Range:	0.49 – 1.54
Shares Outstanding (million):	71
Market cap ($million):	$47
EV ($million):	$42
Debt ($million):	$12
Cash ($million):	$17
Avg. Daily Trading Vol. ($million):	$0.2
Float (million shares):	43
Short Interest (million shares):	2
Dividend, annual (yield):	$0 (NA%)

Revenues (US$ million)

	2023E (Cur.)	2023E (Old)	2024E (Cur.)	2024E (Old)
Q1 Mar	0A	0E	0E	
Q2 Jun	0E		0E	
Q3 Sep	0E		0E	
Q4 Dec	0E		0E	
Total	**0E**		**0E**	
EV/Revs	N/A		N/A	

Earnings per Share (pro forma)

	2023E (Cur.)	2023E (Old)	2024E (Cur.)	2024E (Old)
Q1 Mar	(0.16)A	(0.13)E	(0.13)E	
Q2 Jun	(0.13)E		(0.13)E	
Q3 Sep	(0.13)E		(0.13)E	
Q4 Dec	(0.13)E		(0.13)E	
Total	**(0.56)E**	**(0.53)E**	**(0.53)E**	**(0.52)E**
P/E	N/A		N/A	

Exhibit 1: NRx Pharmaceuticals, Inc. Corporate Overview

Source: Company reports.

Exhibit 2: NRx's Investment Summary



Source: Company reports.

Exhibit 3: NRX-101





Source: Company reports.

Exhibit 4: NRx's Product Pipeline



NRx R&D Pipeline:
Multi-Billion Dollar Potential in Psychiatry and Chronic Pain

Indication	Compound	Preclinical	Phase 1	Phase 2	Phase 3	Status
Bipolar Depression & Suicidal Ideation						
Severe Bipolar Depression with Recently Suicidal Patients post stabilization	NRX-100™ / NRX-101™	FDA SPA, Breakthrough Therapy, Biomarker letter of Support				*Integrating with P2b/3*
Treatment of Suicidal Treatment-Resistant Bipolar Depression	NRX-101™	Currently Enrolling Phase 2b/3				Data expected Q4 2023
Expanded Access / Safety Study	NRX-101™	300+ expected to be enrolled by Q2 2024				
Post-Traumatic Stress Disorder (PTSD) with Depression & Suicidality						
PTSD in patients with Depression & Suicidality	NRX-101™	Enrollment pending				Data readout expected in 2023
Chronic Pain with depression						
Depression in patients with chronic pain	NRX-101™	Planning				Data readout expected in 2024

Source: Company reports.

Exhibit 5: Targeting Suicidal Bipolar Depression Risks



Source: Company reports.

Exhibit 6: Bipolar Depression Suicide Market Opportunities



Source: Company reports.

Exhibit 7: Unmet Need for Bipolar Depression Suicidality



Source: Company reports.

Exhibit 8: Science of Depression and Suicidality



Source: Company reports.

Exhibit 9: NRx Discovery





Source: Company reports.

Exhibit 10: Phase 2 Study of D-Cycloserine in Depression / Suicidality Conclusions

Phase 2 Study showed effect of D-Cycloserine in Depression / Suicidality

If Phase 2 results are replicated in Phase 3, this will meet criteria for FDA approval

- Primary endpoint is mean MADRS score over 42 days
- A clinically and statistically significant difference (p=.03) was seen on the mixed model through day 42. The mean 7.7 point difference on MADRS is similar to or larger than that seen with Esketamine
- 40% relapse in control group, no relapse in NRX-101 group
- Patients who would otherwise have been in the hospital for 1 week plus were discharged after 1-2 days



Source: Company reports.

Exhibit 11: Current NRX-101 Clinical Trial Program (SSIB & ASIB)



Source: Company reports.

Exhibit 12: NRX-101 Advantages and Objectives

NRX-101 offers a differentiated profile for Suicidal Bipolar Depression with an FDA agreed upon path to NDA

Phase 3 with FDA Breakthrough Therapy designation

NMDA – A Validated Mechanism
- Depression & Suicidality
- Esketamine, NRX-101 Phase 2, etc.

FDA Agreed Upon Regulatory Path
- Special Protocol Agreement, Breakthrough Therapy designation: Treatment of Severe Bipolar Depression in Patients with ASIB after initial stabilization with ketamine or other effective therapy

Addresses High Unmet Need
- Treats depression and suicidality (bipolar space)
- Oral, not addictive (not scheduled), avoids hallucinations
- Outpatient

Efficient Clinical Development Path to NDA
- Seeking to replicate P2 study
- NRX-100 (144 pts.) NRX-101 (~80 pts.) pivotal study (severely depressed and acutely suicidal) to start 2H22
- Path to NDA filing in 2023

Path to NDA

Exploring expansion in earlier population
- NRX-101 Phase 2 trial (Bipolar Depression in sub-acute suicidality) initiated 2Q 2022

Composition of Matter Patent
- NRx has a composition of matter patent for NRX-101 and an array of NMDA+5HT2A compounds,
- Five patent families, 60+ applications, 30+ issued patents

Source: Company reports.

Exhibit 13: NRX-101 Market Opportunities

NRX-101 could be a potential Paradigm Shift in the Treatment of High Unmet Psychiatric Conditions – especially those with Suicidality

Bipolar Depression with Suicidality:
- ASIB: Rapid stabilization with ketamine and discharge after 1-2 days with oral, non-addictive drug
- SSIB: Periodic use when suicidality present



PTSD with and without Suicidality:
- ~9M (3.6%) of US adult population had PTSD in the last year, of which 1/3 had severe PTSD
- Up to 10% may attempt suicide / have suicidality
- Only 2 drugs indicated for PTSD, limited efficacy and carry warning for increased risk of suicide



Source: Company reports.

Exhibit 14: NRX-101 for PTSD



Source: Company reports.

Exhibit 15: NRX-101 DSMB and FDA recommendations (as of April 2023)

Source: Company reports.

Exhibit 16: Q1 2023 and Recent Business Highlights

- Enrollment continues in the Phase 2b/3 clinical trial evaluating NRX-101 in Suicidal Treatment-Resistant Bipolar Depression; data expected in 4Q 2023
- National educational campaign launched to further accelerate enrollment in
- Breakthrough Therapy Designation meeting for NRX-101 in Suicidal Treatment-Resistant Bipolar Depression with the U.S. FDA planned for 2Q 2023; on track to report topline clinical data in 4Q 2023
- Ended quarter with $16.5 million in cash and cash equivalents

First Quarter Corporate Updates

- In February 2023, the Company received notice of the issuance of a U.S. patent covering the lead formulation, NRX-101, a glycine site NMDA antagonist in clinical trials to treat bipolar depression with acute and subacute suicidality. This new patent covers the use of NRX-101 to treat patients suffering from depression, including bipolar depression or major depression (MDD) with or without suicidality and strengthens the Company's intellectual property position until at least 2033.
- In March 2023, the Company announced the close of a $2.9 million registered direct offering. Participants were existing investors, and the Company anticipates using the proceeds to initiate its national treatment protocol and safety database for NRX-101 for treatment-resistant bipolar depression with risk of self-harm under an FDA expanded access protocol, and to advance its pipeline of life-saving therapeutics.
- The Company has continued to engage in a strategic conversation focused on funding the drug approval and commercialization. In parallel, the Company has established an ongoing dialogue with Streeterville Capital LLC, the Company's current debt lender, to modify the Company's current debt facility to best support the ongoing needs of the clinical trial.

Source: Company reports.

Exhibit 17: NRx Pharmaceuticals, Inc. Stock Price (5-Years)

SPAC (Big Rock Partners Acquisition Corp.) IPO - 11/20/17

SPAC Merger Announcement (with NeuroRx, Inc.) - 12/14/20

SPAC Merger Completion (to form NRx Pharmaceuticals, Inc.) - 5/25/21



Source: https://bigcharts.marketwatch.com/

Exhibit 18: Consensus Expectations (as of May 16, 2023)

	Revenue (mil)			EPS	
	2023E	2024E		2023E	2024E
Q1 Mar	$0E		Q1 Mar	$(0.14)E	
Q2 Jun	$0E		Q2 Jun	$(0.13)E	
Q3 Sep			Q3 Sep		
Q4 Dec			Q4 Dec		
Total	$0E	$0E	Total	$(0.51)E	$(0.35)E

**Quarterly estimates may not add to annual estimates due to variations in contributing estimates and rounding.*

Source: Company report, Refinitiv, and Ascendiant Capital Markets estimates

FINANCIAL MODEL

NRx Pharmaceuticals, Inc.

Income Statement ($ mils)	Mar-21	Jun-21	Sep-21	Dec-21	2021	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Total Revenue	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**
Cost of Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross Profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Research & development	2.9	4.7	6.3	6.4	20.3	5.5	3.0	4.1	4.5	17.0	3.7	4.0	4.0	4.0	15.7	4.3	4.3	4.3	4.3	17.0
General and administrative	2.1	12.5	13.8	46.6	74.9	10.2	6.6	5.0	5.5	27.4	5.8	5.0	5.0	5.0	20.8	5.0	5.0	5.0	5.0	20.0
Restructuring and other	20.6				20.6					0.0					0.0					0.0
Total operating expenses	25.6	17.1	20.1	53.0	115.8	15.7	9.6	9.1	10.0	44.4	9.4	9.0	9.0	9.0	36.4	9.3	9.3	9.3	9.3	37.0
Operating income (loss)	**(25.6)**	**(17.1)**	**(20.1)**	**(53.0)**	**(115.8)**	**(15.7)**	**(9.6)**	**(9.1)**	**(10.0)**	**(44.4)**	**(9.4)**	**(9.0)**	**(9.0)**	**(9.0)**	**(36.4)**	**(9.3)**	**(9.3)**	**(9.3)**	**(9.3)**	**(37.0)**
Interest income (expense)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	0.1	0.1	0.2	0.2	(0.4)	(0.4)	(0.4)	(1.1)	(0.4)	(0.4)	(0.4)	(0.4)	(1.7)
Other income (expense)	0.1	(238.8)	(0.7)	6.3	(233.1)	2.3	2.6	(0.0)	(0.5)	4.3	(1.8)	0.0	0.0	0.0	(1.8)	0.0	0.0	0.0	0.0	0.0
Income before income taxes	(25.5)	(255.9)	(20.8)	(46.7)	(348.9)	(13.4)	(7.0)	(9.1)	(10.3)	(39.8)	(11.0)	(9.4)	(9.4)	(9.4)	(39.3)	(9.7)	(9.7)	(9.7)	(9.7)	(38.7)
Income taxes					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income (loss)	(25.5)	(255.9)	(20.8)	(46.7)	(348.9)	(13.4)	(7.0)	(9.1)	(10.3)	(39.8)	(11.0)	(9.4)	(9.4)	(9.4)	(39.3)	(9.7)	(9.7)	(9.7)	(9.7)	(38.7)
Nonrecurring/noncash adjustments		(12.5)			0.0					0.0					0.0					0.0
Net income (pro forma)	**(25.5)**	**(268.4)**	**(20.8)**	**(46.7)**	**(348.9)**	**(13.4)**	**(7.0)**	**(9.1)**	**(10.3)**	**(39.8)**	**(11.0)**	**(9.4)**	**(9.4)**	**(9.4)**	**(39.3)**	**(9.7)**	**(9.7)**	**(9.7)**	**(9.7)**	**(38.7)**
EBITDA																				
Shares, Basic	35.7	41.7	51.7	58.5	46.9	63.7	65.7	66.4	67.5	65.8	67.5	70.3	70.8	71.3	70.0	71.8	72.3	72.8	73.3	72.6
Shares, Diluted	35.7	42.5	51.7	58.5	46.9	63.7	65.7	66.4	67.5	65.8	67.5	70.3	70.8	71.3	70.0	71.8	72.3	72.8	73.3	72.6
EPS Basic (pro forma)	**($0.71)**	**($6.43)**	**($0.40)**	**($0.80)**	**($7.44)**	**($0.21)**	**($0.11)**	**($0.14)**	**($0.15)**	**($0.61)**	**($0.16)**	**($0.13)**	**($0.13)**	**($0.13)**	**($0.56)**	**($0.13)**	**($0.13)**	**($0.13)**	**($0.13)**	**($0.53)**
EPS Diluted (pro forma)	($0.71)	($6.32)	($0.40)	($0.80)	($7.44)	($0.21)	($0.11)	($0.14)	($0.15)	($0.61)	($0.16)	($0.13)	($0.13)	($0.13)	($0.56)	($0.13)	($0.13)	($0.13)	($0.13)	($0.53)
Margins																				
Gross margin																				
Research & development																				
General and administrative																				
Operating margin																				
Tax rate, GAAP																				
Net margin																				
Y/Y % change																				
Total Revenue																				
Gross margin																				
Research & development					91%	88%	-37%	-34%	-31%	-16%	-33%	35%	-3%	-10%	-8%	16%	6%	6%	6%	9%
General and administrative					555%	387%	-47%	-64%	-88%	-63%	-43%	-25%	0%	-9%	-24%	-14%	0%	0%	0%	-4%
Operating income (loss)					125%	-39%	-44%	-55%	-81%	-62%	-40%	-6%	-2%	-10%	-18%	-2%	3%	3%	3%	2%
Net income (loss)					574%	-47%	-97%	-56%	-78%	-89%	-18%	35%	4%	-9%	-1%	-12%	3%	3%	3%	-2%
EPS Diluted (pro forma)					392%	-70%	-98%	-66%	-81%	-92%	-23%	26%	-3%	-13%	-7%	-18%	0%	0%	0%	-5%

Source: Company reports and Ascendiant Capital Markets estimates.

NRx Pharmaceuticals, Inc.

Balance Sheet ($ mils)	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Assets																
Cash and cash equivalents	13.3	13.4	38.9	27.6	40.2	24.5	18.2	20.1	16.5	14.7	8.9	5.2	(3.9)	(17.9)	(26.8)	(30.9)
Short term investments										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Account receivable																
Deferred income taxes										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses and other	0.3	5.1	6.4	5.1	3.4	7.9	6.6	5.7	5.3	5.3	2.3	2.3	2.3	2.3	2.3	2.3
Total current assets	13.6	18.5	45.2	32.7	43.6	32.4	24.8	25.8	21.8	19.9	11.2	7.4	(1.6)	(15.6)	(24.6)	(28.7)
Property and equipment, net										0.1	0.1	0.1	0.2	0.2	0.2	0.3
Intangibles, net										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income tax										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total assets	**13.6**	**18.5**	**45.3**	**32.7**	**43.6**	**32.4**	**24.8**	**25.8**	**21.8**	**20.0**	**11.3**	**7.6**	**(1.4)**	**(15.4)**	**(24.4)**	**(28.3)**
Liabilities and stockholders' equity																
Accounts payable	4.4	6.3	5.6	3.7	4.3	3.1	2.2	2.1	3.8	3.8	3.8	3.8	3.8	3.8	3.8	3.8
Accrued expenses	2.1	2.6	3.2	2.8	4.5	4.0	5.8	5.8	6.1	6.1	6.1	6.1	6.1	6.1	6.1	6.1
Deferred income tax										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Warrant liabilities		0.5	0.8	0.3	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	25.9	26.3	4.6	2.5					0.0	0.0	0.0	0.0	0.0	0.0	0.0
Short term debt	0.2	0.2	0.5	0.5	0.5			8.7	12.2	12.2	12.2	12.2	12.2	12.2	12.2	12.2
Total current liabilities	**6.7**	**35.5**	**36.3**	**11.9**	**11.9**	**7.1**	**8.0**	**16.6**	**22.1**	**22.1**	**22.1**	**22.1**	**22.1**	**22.1**	**22.1**	**22.1**
Deferred income taxes										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Warrant liabilities										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long term liabilities										7.0	7.0	12.0	12.0	7.0	7.0	12.0
Long term debt	0.5	0.5						1.8		0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total other liabilities	**0.5**	**0.5**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**1.8**	**0.0**	**7.0**	**7.0**	**12.0**	**12.0**	**7.0**	**7.0**	**12.0**
Common stock	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.8	1.5	2.2	2.9	3.5	4.2	4.9
Additional paid-in capital	122.0	114.2	161.4	204.0	228.3	229.0	229.5	230.4	233.6	233.6	233.6	233.6	233.6	233.6	233.6	233.6
Retained earnings	(115.7)	(131.7)	(152.4)	(183.2)	(196.7)	(203.7)	(212.8)	(223.1)	(234.0)	(243.5)	(252.9)	(262.3)	(272.0)	(281.7)	(291.3)	(301.0)
Other										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accumulated other comprehensive income									0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Total stockholders' equity	**6.4**	**(17.4)**	**9.0**	**20.8**	**31.7**	**25.4**	**16.8**	**7.4**	**(0.3)**	**(9.0)**	**(17.7)**	**(26.5)**	**(35.5)**	**(44.4)**	**(53.4)**	**(62.4)**
Total stockholders' equity and liabil	**13.6**	**18.5**	**45.3**	**32.7**	**43.6**	**32.4**	**24.8**	**25.8**	**21.8**	**20.0**	**11.3**	**7.6**	**(1.4)**	**(15.4)**	**(24.4)**	**(28.3)**

Balance Sheet Drivers

	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24
	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Book & Cash Value (per share)																
Book Value per Share (diluted)	$0.18	($0.41)	$0.17	$0.36	$0.50	$0.39	$0.25	$0.11	($0.00)	($0.13)	($0.25)	($0.37)	($0.49)	($0.61)	($0.73)	($0.85)
Cash per Share (diluted)	$0.37	$0.32	$0.75	$0.47	$0.63	$0.37	$0.27	$0.30	$0.24	$0.21	$0.13	$0.07	($0.05)	($0.25)	($0.37)	($0.42)
Net cash per Share (diluted)	$0.35	$0.30	$0.74	$0.46	$0.62	$0.37	$0.27	$0.14	$0.06	$0.04	($0.05)	($0.10)	($0.22)	($0.42)	($0.54)	($0.59)

Source: Company reports and Ascendiant Capital Markets estimates

NRx Pharmaceuticals, Inc.

Cash Flow Statement ($ mils)	Mar-21	Jun-21	Sep-21	Dec-21	2021	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Cash flow from operating activities																				
Net income	(25.5)	(0.1)	(36.7)	(30.8)	(93.1)	(13.4)	(7.0)	(9.1)	(10.2)	(39.8)	(11.0)	(9.4)	(9.4)	(9.4)	(39.3)	(9.7)	(9.7)	(9.7)	(9.7)	(38.7)
Depreciation		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortization					0.0					0.0					0.0					0.0
Debt related amortization expen	0.0	0.0	0.0	0.0	0.0	0.0	(0.0)	0.0	0.0	0.0					0.0					0.0
Stock comp	0.4	9.1	9.5	42.6	61.6	1.3	1.0	0.5	0.8	3.6	0.7	0.7	0.7	0.7	2.8	0.7	0.7	0.7	0.7	2.8
Deferred income taxes					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Change in fair value of warrant liability		(17.4)	16.2	(0.5)	(1.7)	(0.2)	(0.1)	0.0	0.5	0.3	1.8				1.8					0.0
Change in fair value of earnout cash liabil		0.4	0.4	(21.7)	(20.9)	(2.1)	(2.5)			(4.6)										
Writedowns and impairments					0.0					0.0					0.0					0.0
Other gains/losses	(0.1)		0.0	(0.0)	(0.1)					0.0					0.0					0.0
Other	21.4		(0.0)	0.0	21.4					0.0					0.0					0.0
Changes in operating assets and liabilities:																				
Accounts receivable	0.8		0.0	(0.0)	0.8					0.0					0.0					0.0
Prepaid expenses & other curre	(0.1)	(4.8)	(1.2)	1.2	(4.8)	1.7	(4.5)	1.3	0.8	(0.6)	0.5		3.0		3.5					0.0
Income tax					0.0					0.0					0.0					0.0
Other assets					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	1.2	1.3	(0.7)	(1.9)	(0.0)	0.6	(1.2)	(0.9)	(0.1)	(1.6)	1.7				1.7					0.0
Accrued expenses	(1.2)	0.1	0.5	(0.3)	(0.9)	1.6	(0.5)	1.8	(0.0)	2.9	0.3				0.3					0.0
Other liabilities					0.0					0.0		7.0	0.0	5.0	12.0	0.0	(5.0)	0.0	5.0	0.0
Net cash (used in) provided by	**(3.0)**	**(11.4)**	**(12.0)**	**(11.3)**	**(37.7)**	**(10.4)**	**(14.8)**	**(6.3)**	**(8.3)**	**(39.8)**	**(6.1)**	**(1.7)**	**(5.7)**	**(3.7)**	**(17.3)**	**(9.0)**	**(14.0)**	**(9.0)**	**(4.0)**	**(35.9)**
Cash flow from investing activities																				
Purchases of property and equipment		(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	(0.0)	(0.0)	(0.1)	(0.0)	(0.0)	(0.1)	(0.1)	(0.0)	(0.0)	(0.1)	(0.2)
Purchases of short-term investments					0.0					0.0					0.0					0.0
Acquisitions					0.0					0.0					0.0					0.0
Other					0.0					0.0					0.0					0.0
Net cash used in investing activ	**0.0**	**(0.0)**	**(0.0)**	**(0.0)**	**(0.0)**	**(0.0)**	**(0.0)**	**(0.0)**	**0.0**	**(0.0)**	**(0.0)**	**(0.1)**	**(0.0)**	**(0.0)**	**(0.1)**	**(0.1)**	**(0.0)**	**(0.0)**	**(0.1)**	**(0.2)**
Cash flow from financing activities																				
Issuance of debt					0.0				10.0	10.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Repayment of debt		(1.1)	(0.2)	0.0	(1.3)		(0.5)			(0.5)					0.0					0.0
Issuance of stock	6.9	1.6	28.5	0.0	37.0	23.0	(0.3)	(0.0)	0.1	22.7	2.5	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0
Proceeds from stock option exe	7.5		9.2	(0.0)	16.7				0.0	0.0					0.0					0.0
Other		11.1	(0.0)	0.0	11.1					0.0					0.0					0.0
Dividends and distributions					0.0					0.0					0.0					0.0
Cash provided by (used in) fina	**14.4**	**11.5**	**37.5**	**0.0**	**63.5**	**23.0**	**(0.9)**	**(0.0)**	**10.1**	**32.2**	**2.5**	**0.0**	**0.0**	**0.0**	**2.5**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**
Effect of exchange rate on cash					0.0					0.0					0.0					0.0
Net increase (decrease) in cash	**11.4**	**0.1**	**25.5**	**(11.3)**	**25.7**	**12.6**	**(15.7)**	**(6.3)**	**1.8**	**(7.6)**	**(3.5)**	**(1.8)**	**(5.7)**	**(3.7)**	**(14.9)**	**(9.1)**	**(14.0)**	**(9.0)**	**(4.1)**	**(36.1)**
Beginning cash and equivalents	**1.9**	**13.3**	**13.4**	**38.9**	**1.9**	**27.6**	**40.2**	**24.5**	**18.2**	**27.6**	**20.1**	**16.5**	**14.7**	**8.9**	**20.1**	**5.2**	**(3.9)**	**(17.9)**	**(26.8)**	**5.2**
Ending cash and equivalents	**13.3**	**13.4**	**38.9**	**27.6**	**27.6**	**40.2**	**24.5**	**18.2**	**20.1**	**20.1**	**16.5**	**14.7**	**8.9**	**5.2**	**5.2**	**(3.9)**	**(17.9)**	**(26.8)**	**(30.9)**	**(30.9)**

Source: Company reports and Ascendiant Capital Markets estimates

ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendiant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

NRx Pharmaceuticals, Inc.

- Ascendiant Capital Markets, LLC has received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendiant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendiant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof.

Risks & Considerations

Risks to attainment of our share price target include balance sheet/liquidity risks, failure of product candidates to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approvals, ability to commercialize product, failure to obtain suitable reimbursement, competition, changing macroeconomic factors, investor sentiment for investing in biotech stocks, and changes in consumer or government priorities for healthcare.

Ascendiant Capital Markets, LLC Rating System

BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.

HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendiant Capital Markets, LLC Distribution of Investment Ratings (as of April 14, 2023)

			Investment Banking Services Past 12 months	
Rating	**Count**	**Percent**	**Count**	**Percent**
Buy	49	98%	18	37%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	50	100%	18	36%

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendiant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendiant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendiant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendiant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendiant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendiant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendiant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendiant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendiant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.